".. while measured neutralising antibody titres generated by vaccination with ChAdOx1 nCoV-19 vaccine are lower for the B.1.1.7 lineage, clinical efficacy of the vaccine against symptomatic COVID disease is similar between B.1.1.7 and non-B.1.1.7 lineages" - preprint in the QT... https://twitter.com/JennerInstitute/status/1357683814034726912

"Minimum Ct values (an inverse proxy for peak viral load) from Lighthouse lab swabs in ChAdOx1 nCoV-19 vaccinated participants were higher than in those who received the control vaccine (p<0.0001) and participants were PCR-positive for a shorter period of time (p<0.0001)."

One quote relates to over-interpreting in vitro serum neutralisation assays as loss of vaccine efficacy: "These findings suggest that either lower nAb titres are sufficient to provide protection or that other mechanisms of immunity may be responsible for protection ...."

"The protection against this new variant, described here, is an important finding for regions where B.1.1.7 is now the dominant variant and vaccine programmes are already underway."

My immediate take homes are...

1) The AZ vaccine protects against B.1.1.7, but again, the virus seems to be firing "warning shots".

2) The AZ vaccine reduces viral load/shedding (so likely transmission)

3) Much more T cell work is currently underway

Aha... this arrived at the right time. Given the high B117 prevalence of B117, it’s good that the AZ vaccine works against this particular variant. Cheers @alanmcn1, right on cue. https://twitter.com/alanmcn1/status/1357701944027004929